FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010147963> ?p ?o ?g. }

• W2010147963 endingPage "235" @default.
• W2010147963 startingPage "227" @default.
• W2010147963 abstract "HR325 (2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'(trifluoromethyl)-phenyl]-propenamide) is an immunomodulatory compound through pyrimidine biosynthesis inhibition with antiproliferative properties which was derived from the isoxazol compound A77 1726 [2-cyano-3-cyclopropyl-3-hydroxy-enoic acid (4-trifluoromethylphenyl)-amide]. During studies of the effects on early signal transduction events of this type of compound, it was found that HR325 dose-dependently inhibited adenosine 3',5'-cyclic monophosphate (cAMP) synthesis by Jurkat cells stimulated with prostaglandin E(2), (PGE(2)), cholera toxin (CTX), or forskolin (FKN). The potency of inhibition by HR325 of FKN-stimulated cells (IC(50) 30.4 microM) was approximately 3-fold higher than that of the other agonists (11.6 and 11.7 microM) and was independent of time of preincubation for both PGE(2) and FKN. Interestingly, A77 1726, an analogue of HR325, displayed a markedly different profile of stimulus-dependent potencies. The inhibition of cAMP synthesis by HR325 when stimulated by both PGE(2) and FKN was unaffected by glucose supplementation, in contrast to HR325-inhibited ATP levels, which were restored under such conditions. Further studies revealed that HR325 reduced intracellular ATP levels by uncoupling oxidative phosphorylation, albeit with a 1000-fold lower potency than the antihelmintic drug niclosamide. In addition, glucose supplementation experiments showed that, in contrast to HR325, the niclosamide-mediated reduction of ATP levels was wholly responsible for its inhibition of PGE(2)- and FKN-stimulated cAMP synthesis." @default.
• W2010147963 created "2016-06-24" @default.
• W2010147963 creator A5009500424 @default.
• W2010147963 creator A5036611479 @default.
• W2010147963 creator A5053067336 @default.
• W2010147963 creator A5056115689 @default.
• W2010147963 creator A5077985842 @default.
• W2010147963 creator A5079053463 @default.
• W2010147963 creator A5089164675 @default.
• W2010147963 date "2001-01-01" @default.
• W2010147963 modified "2023-09-25" @default.
• W2010147963 title "Inhibition of stimulated Jurkat cell adenosine 3′,5′-cyclic monophosphate synthesis by the immunomodulatory compound HR32577Abbreviations: PGE2, prostaglandin E2; FKN, forskolin; CTX, cholera toxin; cAMP, adenosine 3′,5′-cyclic monophosphate; IBMX, 3-isobutyl-1-methylxanthine; NCA, niclosamide; FCCP, carbonyl cyanide p-trifluoromethoxyphenyl hydrazone; DHO-DH, dihydroorotate dehydrogenase; IL-2, interleukin-2; and HBSS, Hanks’ balanced salt solution." @default.
• W2010147963 cites W1551770211 @default.
• W2010147963 cites W1572273862 @default.
• W2010147963 cites W1576297032 @default.
• W2010147963 cites W1605619919 @default.
• W2010147963 cites W164548000 @default.
• W2010147963 cites W1777971977 @default.
• W2010147963 cites W1815523758 @default.
• W2010147963 cites W1964717435 @default.
• W2010147963 cites W1967704295 @default.
• W2010147963 cites W1981690748 @default.
• W2010147963 cites W1985135899 @default.
• W2010147963 cites W1987175676 @default.
• W2010147963 cites W1988935381 @default.
• W2010147963 cites W1989377439 @default.
• W2010147963 cites W1990680114 @default.
• W2010147963 cites W2010861152 @default.
• W2010147963 cites W2020756415 @default.
• W2010147963 cites W2021137024 @default.
• W2010147963 cites W2025344936 @default.
• W2010147963 cites W2033485979 @default.
• W2010147963 cites W2038529352 @default.
• W2010147963 cites W2054218135 @default.
• W2010147963 cites W2054384440 @default.
• W2010147963 cites W2057853327 @default.
• W2010147963 cites W2058076066 @default.
• W2010147963 cites W2058692804 @default.
• W2010147963 cites W2065576227 @default.
• W2010147963 cites W2079855969 @default.
• W2010147963 cites W2081623704 @default.
• W2010147963 cites W2091957204 @default.
• W2010147963 cites W2112941906 @default.
• W2010147963 cites W2161341063 @default.
• W2010147963 cites W2196047403 @default.
• W2010147963 doi "https://doi.org/10.1016/s0006-2952(00)00552-9" @default.
• W2010147963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11163337" @default.
• W2010147963 hasPublicationYear "2001" @default.
• W2010147963 type Work @default.
• W2010147963 sameAs 2010147963 @default.
• W2010147963 citedByCount "6" @default.
• W2010147963 countsByYear W20101479632012 @default.
• W2010147963 countsByYear W20101479632018 @default.
• W2010147963 countsByYear W20101479632019 @default.
• W2010147963 countsByYear W20101479632021 @default.
• W2010147963 crossrefType "journal-article" @default.
• W2010147963 hasAuthorship W2010147963A5009500424 @default.
• W2010147963 hasAuthorship W2010147963A5036611479 @default.
• W2010147963 hasAuthorship W2010147963A5053067336 @default.
• W2010147963 hasAuthorship W2010147963A5056115689 @default.
• W2010147963 hasAuthorship W2010147963A5077985842 @default.
• W2010147963 hasAuthorship W2010147963A5079053463 @default.
• W2010147963 hasAuthorship W2010147963A5089164675 @default.
• W2010147963 hasConcept C126322002 @default.
• W2010147963 hasConcept C134018914 @default.
• W2010147963 hasConcept C170493617 @default.
• W2010147963 hasConcept C185592680 @default.
• W2010147963 hasConcept C2776668983 @default.
• W2010147963 hasConcept C2776766087 @default.
• W2010147963 hasConcept C2776991684 @default.
• W2010147963 hasConcept C2777006276 @default.
• W2010147963 hasConcept C2777956040 @default.
• W2010147963 hasConcept C2779276759 @default.
• W2010147963 hasConcept C2781298581 @default.
• W2010147963 hasConcept C55493867 @default.
• W2010147963 hasConcept C71924100 @default.
• W2010147963 hasConcept C86803240 @default.
• W2010147963 hasConcept C98274493 @default.
• W2010147963 hasConceptScore W2010147963C126322002 @default.
• W2010147963 hasConceptScore W2010147963C134018914 @default.
• W2010147963 hasConceptScore W2010147963C170493617 @default.
• W2010147963 hasConceptScore W2010147963C185592680 @default.
• W2010147963 hasConceptScore W2010147963C2776668983 @default.
• W2010147963 hasConceptScore W2010147963C2776766087 @default.
• W2010147963 hasConceptScore W2010147963C2776991684 @default.
• W2010147963 hasConceptScore W2010147963C2777006276 @default.
• W2010147963 hasConceptScore W2010147963C2777956040 @default.
• W2010147963 hasConceptScore W2010147963C2779276759 @default.
• W2010147963 hasConceptScore W2010147963C2781298581 @default.
• W2010147963 hasConceptScore W2010147963C55493867 @default.
• W2010147963 hasConceptScore W2010147963C71924100 @default.
• W2010147963 hasConceptScore W2010147963C86803240 @default.
• W2010147963 hasConceptScore W2010147963C98274493 @default.
• W2010147963 hasIssue "2" @default.
• W2010147963 hasLocation W20101479631 @default.
• W2010147963 hasLocation W20101479632 @default.
• W2010147963 hasOpenAccess W2010147963 @default.
• W2010147963 hasPrimaryLocation W20101479631 @default.

• next